Clinical study on CXCL13, CCL17, CCL20 and IL-17 as immune cell migration navigators in relapsing remitting multiple sclerosis patients
Clinical study on CXCL13, CCL17, CCL20 and IL-17 as immune cell migration navigators in relapsing remitting multiple sclerosis patients
复制标题
DOI：
10.1016/j.jns.2010.09.026
复制
发表时间：
2011-01-15
影响因子：
4.4
通讯作者：
Losy, Jacek
中科院分区：
文献类型：
--
作者：
Kalinowska-Lyszczarz, Alicja;Szczucinski, Adam;Losy, Jacek
背景：越来越多的证据表明趋化因子在多发性硬化的病理学中的作用。近年来，体液免疫和T（H）-17免疫反应受到了广泛关注，但在MS中尚未得到充分的描述。本研究的目的是研究参与B细胞迁移（CXCL 13）和T（H）-17免疫反应的特异性趋化因子的作用方法：采用ELISA法检测复发缓解型MS患者血清和脑脊液中趋化因子IL-17、CCL 17、CCL 20的浓度，并计算复发预测率。我们发现，复发和缓解期RRMS患者的CSF中CXCL 13浓度均显著高于对照组。CCL 17和CCL 20在两组的CSF中均未检测到，而血清CCL 20水平在缓解期显著高于复发期。复发患者静脉注射甲基强的松龙治疗不影响血清CXCL 13和CCL 20水平。然而，它确实降低了CCL 17和IL-17concentration.Conclusions：CXCL 13是MS中的重要介质，与疾病的神经炎症活动密切相关。然而，需要更多的研究来阐明CCL 17、CCL 20和IL-17在MS病理学中的作用。(c)2010 Elsevier B. V.保留所有权利。
Background: There has been a growing evidence for the role of chemokines in the pathology of multiple sclerosis. Recently, there has been great emphasis placed on humoral immunity and the T(H)-17 response, which has not yet been thoroughly described in MS. The aim of this study was to investigate the role of specific chemokines involved in B-cell migration (CXCL13) and in the T(H)-17 immune response (IL-17, CCL17, CCL20).Methods: Using ELISA, the chosen chemokine concentrations were measured in the serum and cerebrospinal fluid of relapsing remitting MS patients with both active and stable disease, and the relapse prediction rate was calculated.Results: We found that the CSF concentrations of CXCL13 in patients with RRMS both, during relapse and remission, were significantly higher than in controls. CCL17 and CCL20 were not detected in CSF in either of the groups, whereas serum CCL20 level was significantly higher in remission than during relapse. Intravenous methylprednisolone treatment of patients with relapse did not influence serum CXCL13 and CCL20 levels. However, it did lower CCL17 and IL-17 concentrations.Conclusions: CXCL13 is an important mediator in MS that is strongly linked to the neuroinflammatory activity of the disease. However, more studies are needed for elucidating the roles of CCL17, CCL20 and IL-17 in MS pathology. (c) 2010 Elsevier B.V. All rights reserved.